Gail S. Wright - Concepedia

Author

Gail S. Wright

Florida Cancer Specialists & Research Institute ORCID

Also Known As

G. Wright, G.S. Wright, Gail S Wright, Gail S. Wright, Gail Shaw Wright, Gail Wright, Johnston, Stephen, Wright, Gail S.

Publications

6.4K

Citations

H-Index

Concepts

All Affiliations

Florida Cancer Specialists & Research Institute Tennessee Oncology Sarah Cannon University of California, San Francisco UCSF Helen Diller Family Comprehensive Cancer Center

About

Gail S. Wright is an author at Florida Cancer Specialists & Research Institute specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	235
2	Health Sciences	2	2	143
3	Immunology	2	2	77
4	Cell Biology	1	1	35
5	Obstetrics	1	1	15

Gail S. Wright

Publications

6.3K

Citations

H-Index

Page 1

	Year	Citations
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer Peter Schmid, Sylvia Adams, Hope S. Rugo, New England Journal of Medicine	2018	4.2K
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer David Miles, Joseph Gligorov, Fabrice André, Annals of Oncology	2021	689
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer Hope S. Rugo, Seock‐Ah Im, Fátima Cardoso, JAMA Oncology	2021	336
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial Charles E. Geyer, William M. Sikov, Jens Huober, Annals of Oncology	2022	199
Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non–Small-Cell Lung Cancer Craig H. Reynolds, Coleman K. Obasaju, Michael J. Schell, Journal of Clinical Oncology	2009	172
Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non–Small-Cell Lung Cancer: ECOG 5597 Daniel D. Karp, Sandra J. Lee, Steven M. Keller, Journal of Clinical Oncology	2013	129
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial Antoinette R. Tan, Gail S. Wright, Anu Thummala, The Lancet Oncology Chemotherapy Versus ChemotherapyBreast OncologyMedicineBreast CancerPharmacotherapy	2019	111
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab Melissa M. Hardesty, Thomas C. Krivak, Gail S. Wright, Gynecologic Oncology	2022	95
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial Hope S. Rugo, Seock‐Ah Im, Fátima Cardoso, Journal of Clinical Oncology	2022	74
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study Linda T. Vahdat, Peter Schmid, Andres Forero‐Torres, npj Breast Cancer	2021	52

Page 1